Global /United States /Healthcare /Biotechnology /IGMS

IGM Biosciences, Inc.

IGMS

• NASDAQ: IGMS • Delayed

1.27USD -2.3%

As of 13 June 2026, IGM Biosciences, Inc. has a market cap of $76.57M USD, ranking #27451 globally and #4165 in the United States. It ranks #2466 in the Healthcare sector, and #475 in the Biotechnology industry.

Global Rank

27451

Country Rank

4165

Sector Rank

2466

Industry Rank

475

Key Stats

Market Cap

$76.57MUSD

Enterprise Value

-$27.73MUSD

Revenue (TTM)

$145.05MUSD

EBITDA (TTM)

$17.63MUSD

Net Income (TTM)

-$53.39MUSD

EBITDA Margin

12%

Profit Margin

-37%

PS Ratio

0.5

PB Ratio

0.8

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Mary Harler open_in_new

Employees

149

Founded

1993

IPO

18 Sep 2019

Website

igmbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.3%	0.8%	-5.9%	11%	-6.6%	-79%	-86%	-95%	-98%

News

IGMS Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	IGMS IGM Biosciences Inc Ordinary Shares ISIN: US4495851085 Shares Out.: Shares Outstanding: 36.593M¹ Shares Float: 17.64M² TV: TradingView: NASDAQ: IGMS SA: Stock Analysis: NASDAQ: IGMS YF: Yahoo Finance: IGMS GF: Google Finance: NASDAQ: IGMS NQ: NASDAQ: IGMS BA: Barron's: IGMS MS: Morningstar: XNAS: IGMS	1.27 USD	TV: TradingView: NASDAQ: IGMS SA: Stock Analysis: NASDAQ: IGMS YF: Yahoo Finance: IGMS GF: Google Finance: NASDAQ: IGMS NQ: NASDAQ: IGMS BA: Barron's: IGMS MS: Morningstar: XNAS: IGMS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About IGM Biosciences, Inc.

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 238K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 209K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 36K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 34K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 33K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 24K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 62K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 58K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 55K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 55K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 37K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 33K%	-	Germany

chevron_leftBack